硼替佐米联合多西他赛用于晚期雄激素非依赖性前列腺癌患者的I/II期试验。 - Suppr

Suppr

超能文献

Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.

作者信息

Price Nancy, Dreicer Robert

出版信息

Clin Prostate Cancer. 2004 Dec;3(3):141-3. doi: 10.1016/s1540-0352(11)70076-2.

DOI:10.1016/s1540-0352(11)70076-2

PMID:15636679

Abstract

摘要

相似文献

Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.硼替佐米联合多西他赛用于晚期雄激素非依赖性前列腺癌患者的I/II期试验。

Clin Prostate Cancer. 2004 Dec;3(3):141-3. doi: 10.1016/s1540-0352(11)70076-2.

Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.硼替佐米联合多西他赛用于晚期雄激素非依赖性前列腺癌患者的I/II期研究

Clin Cancer Res. 2007 Feb 15;13(4):1208-15. doi: 10.1158/1078-0432.CCR-06-2046.

Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.每周使用多西他赛和硼替佐米作为激素难治性前列腺癌患者的一线治疗：明妮·珀尔癌症研究网络II期试验

Clin Genitourin Cancer. 2007 Mar;5(4):278-83. doi: 10.3816/CGC.2007.n.004.

Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.硼替佐米联合多西他赛治疗复发性和/或转移性头颈部鳞状细胞癌的 II 期临床试验中核因子-κB 通路及反应。

Ann Oncol. 2010 Apr;21(4):864-870. doi: 10.1093/annonc/mdp390. Epub 2009 Oct 22.

Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.随机Ⅱ期临床试验：硼替佐米联合多西他赛同期或序贯给药治疗晚期非小细胞肺癌——加州癌症联盟研究。

Clin Lung Cancer. 2011 Jan;12(1):33-7. doi: 10.3816/CLC.2011.n.004.

Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.硼替佐米与多西他赛联合用于晚期实体瘤患者的I期试验。

Clin Cancer Res. 2006 Feb 15;12(4):1270-5. doi: 10.1158/1078-0432.CCR-05-1942.

Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.硼替佐米单独使用及硼替佐米联合多西他赛治疗既往接受过治疗的晚期非小细胞肺癌的随机II期研究

J Clin Oncol. 2006 Nov 1;24(31):5025-33. doi: 10.1200/JCO.2006.06.1853.

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.血小板衍生生长因子受体抑制剂甲磺酸伊马替尼与多西他赛：一项针对雄激素非依赖性前列腺癌的Ⅰ期模块化试验

J Clin Oncol. 2004 Aug 15;22(16):3323-9. doi: 10.1200/JCO.2004.10.116.

A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.硼替佐米与泼尼松用于去势抵抗性转移性前列腺癌的II期试验。

J Urol. 2007 Dec;178(6):2378-83; discussion 2383-4. doi: 10.1016/j.juro.2007.08.015. Epub 2007 Oct 22.

Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade.硼替佐米联合激素阻断治疗复发性前列腺癌

Cancer Biol Ther. 2011 Jul 15;12(2):119-24. doi: 10.4161/cbt.12.2.15723.

引用本文的文献

Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.靶向 E3 连接酶 E6AP 恢复前列腺癌中的肿瘤抑制。

Oncogene. 2016 Dec 1;35(48):6235-6245. doi: 10.1038/onc.2016.159. Epub 2016 Sep 19.

High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.高通量转录组分析将蛋白酶体基因确定为前列腺癌中特定年龄的生物标志物和治疗靶点。

Prostate Cancer Prostatic Dis. 2015 Sep;18(3):229-36. doi: 10.1038/pcan.2015.22. Epub 2015 May 19.

Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.硼替佐米敏感性与生存素表达和 p53 状态有关，但与癌细胞类型无关。

J Exp Clin Cancer Res. 2010 Jan 22;29(1):8. doi: 10.1186/1756-9966-29-8.

Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors.使用肌醇六磷酸与蛋白酶体抑制剂联合增强对雄激素非依赖性前列腺癌细胞的杀伤作用。

Br J Cancer. 2008 Nov 18;99(10):1613-22. doi: 10.1038/sj.bjc.6604730. Epub 2008 Oct 21.

Current perspectives in the treatment of advanced prostate cancer.晚期前列腺癌治疗的当前观点

Med Oncol. 2007;24(3):273-86. doi: 10.1007/s12032-007-0017-9.

The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism.蛋白酶体抑制剂MG - 132通过一种不依赖DNA - PK的机制使PC - 3前列腺癌细胞对电离辐射敏感。

BMC Cancer. 2005 Jul 7;5:76. doi: 10.1186/1471-2407-5-76.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验